Galmed initiated with a Buy at Stifel. Stifel analyst Adam Walsh initiated Galmed with a Buy rating and $35 price target, calling it a “legitimate late-stage NASH play” after Aramchol recently proved itself in a Phase 2 trial as a clearly active and “very safe” compound for treating NASH.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.